arrow
A

Anna Ossami Saidy

department of hematology and cell therapy
H指数:4
被引数:81

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis

伊decabtagene vicleucel在复发/难治性多发性骨髓瘤伴先前中枢神经系统表现患者中的疗效:一项多中心真实世界分析

2025-08-180
OA
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

双特异性抗体疗法在复发/难治性大B细胞淋巴瘤中CAR T细胞治疗失败后的疗效

2025-04-190
OA
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

CAR-T失败时间是对复发/难治性大B细胞淋巴瘤双特异性抗体疗法结局的强预测因子

BLOOD
IF23.1
2024-11-051
PRE
Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

伊decabtagene vicleucel(ide-cel)在复发/难治性多发性骨髓瘤且伴有先前中枢神经系统表现患者中的疗效:一项回顾性真实世界分析

BLOOD
IF23.1
2024-11-050
PRE
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
2024-03-207
OAAI